Sector News

Pfizer CEO psychs up investors for a rebate-free world under Trump

August 1, 2018
Life sciences

What would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it.

“I would believe we’re going to go to a marketplace where we don’t have rebates,” he said Tuesday on Pfizer’s second-quarter conference call, noting that such a marketplace “will be very beneficial” to companies “who are launching new products over the next five years or so.”

Pfizer certainly counts itself in that camp. Without what Read referred to as the “rebate trap”—whereby “access is denied to innovative products because of a strong position of another product with its rebates”—its biosimilars could see stronger uptake. Products such as Xeljanz, which Read says has been hurt by rebates from “bigger competitors,” could benefit, too.

The U.S. Office of Management and Budget is currently reviewing a proposed rule from the Trump administration that would remove protections to drug-company rebates, though the rule wouldn’t apply to private payers. Read, though, seems to be thinking further down the line.

“I don’t know the speed of that, but I do believe the administration has been focused” on nixing rebates altogether,” he told analysts.

For now, though, analysts have warned that rule changes may not be so black and white for pharma. The new rules “may not be very simple, and predicting response to any change is equally challenging,” Evercore ISI analyst Josh Schimmer pointed out in a recent note to clients.

The proposed rule is one piece of the administration’s longtime pledge to fight escalating drug prices, a promise the president most recently renewed in a tweet directed at Pfizer itself. In it, he criticized the company’s recent price hikes with a vow that “We will respond!”—a move that spurred the New York drugmaker to reverse the hikes, at least for the time being.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.